<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636827</url>
  </required_header>
  <id_info>
    <org_study_id>sIPV-DTaP-HepA-2020</org_study_id>
    <nct_id>NCT04636827</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA</brief_title>
  <official_title>A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shaanxi Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible,healthy infants who have finished the 3-dose-schedule of sIPV+DTaP combined&#xD;
      vaccination clinical trial (NCT04053010) will be recruited and divided into 4 groups, and&#xD;
      will receive vaccination at the age of 18-month-old as follows:&#xD;
&#xD;
        1. Group 1: sIPV + DTaP + HepA,&#xD;
&#xD;
        2. Group 2: sIPV only,&#xD;
&#xD;
        3. Group 3: DTaP only,&#xD;
&#xD;
        4. Group 4: HepA only.&#xD;
&#xD;
      The immunogenicity and safety of the 4 groups will be compared and analyzed before and 30-40&#xD;
      days after vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the clinical trial of &quot;Combined Immunization of sIPV and DTaP&quot; in 2019, this study&#xD;
      recruits 600 18-month-old subjects who have received 3 doses of sIPV + DTaP, and gives them a&#xD;
      4th dose of vaccination (booster immunization). They are divided into 4 different groups,&#xD;
      with 150 subjects in each group, and are innoculated with different vaccines.&#xD;
&#xD;
      To be specific, group 1 receives sIPV (0.5ml)+ DTaP (0.5ml)+ HepA(0.5ml); group 2 receives&#xD;
      sIPV (0.5ml); group 3 receives DTaP (0.5ml); group 4 receives HepA (0.5ml).&#xD;
&#xD;
      Blood samples will be collected before vaccination and 30-40 days after this booster&#xD;
      immunization. Neutralization antibody will be detected to evaluate the seroprotection rates&#xD;
      and antibody geometric mean concentrations. The safety of both immunization schedule will be&#xD;
      monitored as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate (sIPV)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>determine the rate of positive seroconversion against poliovirus type I, II and III of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (sIPV)</measure>
    <time_frame>Results obtained 30-40 days after vaccination</time_frame>
    <description>determine the rate of positive seroconversion against poliovirus type I, II and III of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (DTaP)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>determine the positive seroconversion rate of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (DTaP)</measure>
    <time_frame>Results obtained 30-40 days after vaccination</time_frame>
    <description>determine the positive seroconversion rate of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (HepA)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>determine the rate of positive seroconversion rate of anti-hepatitis A virus antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (HepA)</measure>
    <time_frame>Results obtained 30-40 days after vaccination</time_frame>
    <description>determine the rate of positive seroconversion rate of anti-hepatitis A virus antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (sIPV)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>GMCs of poliovirus type I, II and III of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (sIPV)</measure>
    <time_frame>Results obtained 30-40 days after vaccination</time_frame>
    <description>GMCs of poliovirus type I, II and III of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (DTaP)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>GMCs of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (DTaP)</measure>
    <time_frame>Results obtained 30-40 days after vaccination</time_frame>
    <description>GMCs of anti-pertussis toxoid , anti- filamentous hemagglutinin, anti-diphtheria toxoid and anti-tetanic antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (HepA)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>GMCs of anti-hepatitis A virus antibody of the subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (HepA)</measure>
    <time_frame>Results obtained 30-40 days after vaccination</time_frame>
    <description>GMCs of anti-hepatitis A virus antibody of the subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Following Immunization (AEFI)</measure>
    <time_frame>0-6 months</time_frame>
    <description>analyse the incidence of adverse events following immunization, both solicited and unsolicited</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>group 1 (sIPV+DTaP+HepA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 (sIPV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3 (DTaP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4 (HepA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sIPV+DTaP+HepA</intervention_name>
    <description>sIPV+DTaP+HepA at the age of 18 month old</description>
    <arm_group_label>group 1 (sIPV+DTaP+HepA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sIPV</intervention_name>
    <description>sIPV at the age of 18 month old</description>
    <arm_group_label>group 2 (sIPV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP</intervention_name>
    <description>DTaP at the age of 18 month old</description>
    <arm_group_label>group 3 (DTaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HepA</intervention_name>
    <description>HepA at the age of 18 month old</description>
    <arm_group_label>group 4 (HepA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have participated the clinical trial titled &quot;Clinic Trial to Evaluate&#xD;
             the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP&quot; (NCT04053010)&#xD;
             in 2019, and have finished 3 doses of combined immunization of sIPV and DTaP;&#xD;
&#xD;
          -  Subjects aged 18-19 months old at the date of recruitment;&#xD;
&#xD;
          -  With informed consent form (ICF) signed by parent(s) or guardian(s);&#xD;
&#xD;
          -  Parent(s) or guardian(s) are able to attend all planned clinical appointments and&#xD;
             obey/follow all study instructions;&#xD;
&#xD;
          -  Subjects have not been vaccinated with sIPV/DTaP/HepA at the age of 18-month-old yet;&#xD;
&#xD;
          -  No less than 14 days since the last dose of vaccination;&#xD;
&#xD;
          -  Axillary temperature ≤37.0℃.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia and&#xD;
             neurological illness;&#xD;
&#xD;
          -  Allergic to any ingredient of vaccine or with allergy history to any vaccine;&#xD;
&#xD;
          -  Subjects with immunodeficency or suspected impairment of immunologic function (e.g.&#xD;
             caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking&#xD;
             orally injecting of steroid hormone);&#xD;
&#xD;
          -  Administration of immunoglobulins within 30 days prior to this study;&#xD;
&#xD;
          -  Acute febrile disease(temperature ≥ 37.0°C) or infectious disease;&#xD;
&#xD;
          -  With a clearly diagnosed history of thrombocytopenia or other coagulopathy, may cause&#xD;
             contraindications for subcutaneous injection;&#xD;
&#xD;
          -  With any serious chronic illness, acute infectious diseases, or respiratory diseases;&#xD;
&#xD;
          -  With severe cardiovascular disease, liver and kidney diseases or diabetes mellitus&#xD;
             with complications;&#xD;
&#xD;
          -  With any kind of infectious, purulent, or allergic skin diseases;&#xD;
&#xD;
          -  With any other factor that makes the investigator determines the subject is unsuitable&#xD;
             for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>19 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaobai Shaobai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaanxi Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaobai Zhang</last_name>
    <phone>+86-29-82231502</phone>
    <email>maolyzhang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <zip>050024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenguo Zhang</last_name>
      <phone>+86-311-86573434</phone>
      <email>hbepi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaobai Zhang</last_name>
      <phone>+86-29-82211350</phone>
      <email>maolyzhang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoying Chang</last_name>
      <phone>+86-351-7553136</phone>
      <email>chshy007@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

